Full Archive
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Clinical Cancer Research 2025 April 10 [Link] Hee-Jin Jang, Meera Patel, Daniel Y Wang, Sung Wook Kang, Jong Min Choi, Claire Lee, Monica Vilchis, Ji Seon Shim, Sonali Mitra, Priyanka Ranchod, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Lenge De Rosen, Maheshwari Ramineni, Ernest Ramsay Camp, Farrah Kheradmand, R Taylor Ripley, Shawn S Groth, Hyun-Sung…
Read MoreHyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review
World Journal of Surgical Oncology 2025 April 9 [Link] Hany Hasan Elsayed, Mohamed Elanany Elsaid Elanany, Mohamed Tarek ElSayegh, Aly Sherif Hassaballa, Mohammed Abdel-Gayed Abstract Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one…
Read MoreGenome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma
Cell Death & Disease 2025 April 3 [Link] Ece Cakiroglu, Sude Eris, Ozden Oz, Gökhan Karakülah, Serif Senturk Abstract Malignant pleural mesothelioma (MPM) is a rare yet highly aggressive malignancy with a severe prognosis. Compounded by the lack of effective treatment modalities, MPM remains a formidable health challenge. Therefore, the identification of actionable liabilities is…
Read MoreUtility and limitations of Merlin immunohistochemistry for mesothelioma diagnosis in tissue sections and cell blocks
Annals of Diagnostic Pathology 2025 August [Link] Kazuki Nabeshima, Makoto Hamasaki, Tomomi Furukawa, Shinji Matsumoto, Katsumi Takizawa, Makiko Adachi, Yuko Goto Abstract Distinguishing pleural mesothelioma (PM) from reactive mesothelial proliferations (RMP) can be challenging. In such cases, immunohistochemistry (IHC)-detected BAP1 or MTAP loss and FISH-detected CDKN2A homozygous deletion are effective. Merlin is the protein product…
Read MoreDiagnostic utility of pleuroscopic guided pleural biopsy versus pleural fluid cell block in the diagnosis of malignant pleural effusion
The Medical Journal of Malaysia 2025 March [Link] B H Ng, H J Low, N N N Abeed, C I Soo, M I Azmi, N S Sharil, R A Osman, M F A Hamid, A Y L Ban Abstract Introduction: Pleural biopsy using flex-rigid pleuroscopy or pleural effusion cell block analysis is useful for diagnosing…
Read MoreEx-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Cancers 2025 March 14 [Link] Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K B Gad, Katalin Dobra Abstract Background/objectives: Non-small cell lung cancer and pleural mesothelioma are among the most lethal and therapy-resistant tumors in humans. These tumors are diagnosed late, frequently present pleural effusion and…
Read MoreDNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma
Cancer Immunology, Immunotherapy 2025 March 25 [Link] Huilin Zhang, Luanxue Yu, Yunqing Guo, Jiawei Ming, Zhenying Guo Abstract Background: Malignant mesothelioma is a highly aggressive cancer with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME) plays a pivotal role in driving tumor progression, with immune cells influencing disease outcomes. However, the molecular…
Read MoreA woman with a pleural mesothelioma and an inherited ATM mutation-a case report
Annals of Translational Medicine 2025 February 28 [Link] Marta Seca, B C John Cho, Angelina Tryon, Steven A Narod Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy primarily linked to asbestos exposure. Up to 80% of patients have a history of such exposure. Several studies have investigated the possibility of a genetic…
Read MoreNew soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma
Journal for Immunotherapy of Cancer 2025 March 17 [Link] Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon Abstract Background: Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction…
Read MoreNew soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma
Journal for Immunotherapy for Cancer 2025 March 17 [Link] Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon Abstract Background: Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction…
Read More